SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-029503
Filing Date
2022-08-15
Accepted
2022-08-15 17:20:09
Documents
49
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q inkt-10q_20220630.htm   iXBRL 10-Q 1222956
2 EX-10.1 inkt-ex101_191.htm EX-10.1 212940
3 EX-31.1 inkt-ex311_6.htm EX-31.1 22060
4 EX-31.2 inkt-ex312_8.htm EX-31.2 22908
5 EX-32.1 inkt-ex321_7.htm EX-32.1 10325
  Complete submission text file 0001564590-22-029503.txt   4234122

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA inkt-20220630.xsd EX-101.SCH 29934
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inkt-20220630_cal.xml EX-101.CAL 26072
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inkt-20220630_def.xml EX-101.DEF 82959
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE inkt-20220630_lab.xml EX-101.LAB 254649
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inkt-20220630_pre.xml EX-101.PRE 178826
43 EXTRACTED XBRL INSTANCE DOCUMENT inkt-10q_20220630_htm.xml XML 524327
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40908 | Film No.: 221166780
SIC: 2836 Biological Products, (No Diagnostic Substances)